Atsena Therapeutics

Atsena's Clinical Ophthalmology Advisor, Dr. Christine Kay, presented promising interim data from our ongoing Phase 1/2 trial of our ocular #GeneTherapy ATSN-201 for the #InheritedRetinalDisease X-linked retinoschisis (#XLRS) at the 2024 American Academy of Ophthalmology (AAO) meeting. The data highlight key safety and efficacy findings, including anatomical improvements like foveal schisis closure and functional visual gains in four of the six patients treated. Read more about the results here:  https://lnkd.in/em5Hd27v Visual description: The image shows a slide that highlights interim safety and efficacy data for the ATSN-201 dose escalation study in patients with X-linked retinoschisis (XLRS). The key finding presented is: "4 of 6 treated eyes had closure of foveal schisis at the most recent visit."   The slide is divided into two cohorts: Cohort 1 (Low Dose): -Subject 1: Optical coherence tomography (OCT) scans at baseline and month 12. -Subject 3: OCT scans at baseline and month 6. Cohort 2 (High Dose): -Subject 4: OCT scans at baseline and month 6. -Subject 6: OCT scans at baseline and month 3.   The OCT images show the retinal structure, with visible foveal schisis (separation of retinal layers) at baseline and significant improvement (closure) in the follow-up scans at the respective months. The slide features Atsena Therapeutics' logo and the header "Data @ AAO.”

October is #BlindnessAwarenessMonth. To help spread awareness, we support Foundation Fighting Blindness and the #ShareYourVision campaign. Whether it’s sharing your unique experiences with or learning more about blinding diseases, we hope you’ll take a moment to inspire others or be inspired.

👀📢 October's FDA Roundup is here... Catch up on latest announcements and approvals from the FDA concerning #Ophthalmology. ◾ Clobetasol: Post-Operative Inflammation and Pain Following Ocular Surgery - Eyenovia, Inc., Michael Rowe ◾ATSN-201: X-Linked Retinoschisis - Atsena Therapeutics, Patrick Ritschel ◾Triesence: Visualization During Vitrectomy and Ocular Inflammatory Conditions - Harrow ◾Alcaftadine Ophthalmic Solution: Itchy Eyes - Alembic Pharmaceuticals Limited ◾MCO-010: Retinitis Pigmentosa - Nanoscope Therapeutics Inc. ◾CLS-AX: Neovascular Age-Related Macular Degeneration - Clearside Biomedical, Inc. ◾OcuCool: Cooling Anesthetic Device - Recens Medical US Read the full article here ➡: https://bit.ly/3MeeGJn --------------------------- #Ophthalmology #Ophthalmologist #EyeHealth #EyeCare #EyeDoctor #EyeCareProfessional #Clobetasol #EyeDrops #OcularInflammation #EyeSurgery #EyeSurgeon #OcularSurgery #OphthalmicSteroid #Pharmaceuticals #ATSN201 #XLinkedRetinoschisis #XLRS #OrphanDrug #RarePediatricDisease #OcularGeneTherapy #GeneTherapy #RetinalDisease #Triesence #Vitrectomy #Corticosteroid #Alcaftadine #OphthalmicSolution #ItchyEyes #MCO010 #RetinitisPigmentosa #BiologicsLicenseApplication #CLSAX #ClinicalTrials #WetAMD #nAMD #AgeRelatedMacularDegeneration #ODYSSEY #NCT05891548 #VisualAcuity #OcuCool #Ocularsurface #MedicalAnesthetics

Atsena co-founder, Shannon Boye, PhD, was recently featured on the What's Your Problem podcast! 🎙️   During this inspiring episode, Dr. Boye dives into our groundbreaking work at Atsena, to pioneer gene therapies that can treat #InheritedRetinalDiseases. She shares the fascinating journey from the early stages of research in blind chickens that led to developing the investigational #GeneTherapy ATSN-101 to treat Leber congenital amaurosis caused by biallelic mutations in GUCY2D (#LCA1).   Dr. Boye also discusses the triumphs and the obstacles that have happened over the years in the ocular gene therapy space and what inspired her to found Atsena.    Listen to the episode here: https://lnkd.in/eG5F46bs

#DYK: An essential tool for navigation, the white cane was introduced in the 1930s to help drivers and pedestrians recognize individuals with visual impairments and to make public spaces more accessible. Over the years, it has become an empowering tool that represents the ability to navigate the world with confidence and autonomy.   On White Cane Safety Day, we reflect on the advances in accessibility and the ongoing work to develop treatments to offer more options for individuals with vision loss. We celebrate the importance of tools like the white cane that help support the strength, independence and resilience of the blind and low vision community. Visual description:   On the left side, text reads: "October 15 is White Cane Safety Day" in bold white and orange letters, set against a deep blue background with light blue curved accents. The lower left corner features the Atsena Therapeutics logo.   On the right side, there’s a photo of two people walking on a dirt path. One person holds a white cane, and both individuals are wearing casual clothing—white sneakers and black pants on one, and darker shoes with blue jeans on the other.

We are excited to announce Christine Kay, MD, will present safety and efficacy data for ATSN-201, our best-in-class investigational #GeneTherapy candidate to treat X-linked retinoschisis (#XLRS), at the upcoming American Academy of Ophthalmology (AAO) 2024 Annual Meeting in Chicago!   ATSN-201 is being evaluated in the LIGHTHOUSE study, a Phase I/II clinical trial in male patients with XLRS due to RS1 gene mutations. To learn more about the AAO 2024 Annual Meeting click here: https://lnkd.in/dFPgwyFg   Visual description: The graphic announces the details of the upcoming presentation at the American Academy of Ophthalmology 2024 Annual Meeting including: Presenter: Christine Nichols Kay, MD Presentation Date & Time: Friday, October 18, 2024, at 5:08 PM CDT Presentation Topic: "Interim Safety and Efficacy of ATSN-201 Dose Escalation Study in Patients with X-linked Retinoschisis(XLRS)" Session: First-time Results of Clinical Trials The background features a gradient from purple to blue, with a picture of Dr. Kay to the right. The Atsena Therapeutics logo is at the bottom right.   https://lnkd.in/ee7YGYFF

Our Director of Patient Advocacy, Kara Fick, had a great time joining Fighting Blindness Canada at View Point Toronto to hear about #InheritedRetinalDiseases and the lived experiences of individuals with vision loss. View Point is an educational series that brings the latest information about vision health and research to the community. As leaders in the field of ocular #GeneTherapy, we are passionate about advancing solutions to reverse or prevent blindness and engaging with the community.   Visual description: A collage of images highlights the VIEW POINT event hosted by Fighting Blindness Canada. It showcases different moments including Atsena’s Director of Patient Advocacy Kara Fick next to a sign that reads "VIEW POINT," a panel discussion with multiple speakers seated on stage with a backdrop displaying the Fighting Blindness Canada logo, another stage featuring two speakers having a conversation and an image of event materials on a table, including a VIEW POINT program, a bag with the Fighting Blindness Canada logo, and various branded items including a pen and magnifying glass. The Atsena Therapeutics logo is at the bottom right.

Exciting news from University of Florida startup Atsena Therapeutics! The FDA has granted Rare Pediatric Disease designation to ATSN-201 for the treatment of X-linked retinoschisis (XLRS). This prestigious designation is reserved for drugs targeting serious conditions that affect fewer than 200,000 patients in the U.S., highlighting the potential of ATSN-201. Leveraging the innovative AAV.SPR capsid, ATSN-201 aims to achieve effective gene expression in central retina photoreceptors while minimizing the risks of foveal detachment. Currently, there are no approved treatments for XLRS, which affects around 30,000 males in the U.S. and EU. This achievement marks the second Rare Pediatric Disease designation granted to Atsena this year! The ongoing LIGHTHOUSE study is evaluating ATSN-201's safety and efficacy in patients aged six and older. Kudos to Atsena for their dedication to transforming the future for those affected by inherited retinal diseases! 👏🔬✨

Atsena is proud to stand with the global community in recognizing World Retina Day, a day dedicated to raising awareness for retinal diseases and the people impacted by them. Retinal diseases, including #InheritedRetinalDiseases (IRDs), affect millions of people worldwide, often leading to vision loss or blindness. We are committed to advancing #GeneTherapy treatments that have the potential to improve sight for those living with IRDs.   Today, we honor the resilience of patients, the dedication of caregivers, and the work of researchers and advocates across the globe. Together, we can illuminate the path toward better vision for all.   Visual description:   The image features a close-up human eye. Circular design elements in blue and orange partially outline the eye. The background is a gradient of deep purple to lighter blue shades. The text on the left side of the image reads:   At the top in a small orange rectangle: "September 29 is" Below it in large white, bold letters: "WORLD RETINA DAY"   The Atsena Therapeutics logo appears in the bottom left corner.

At Atsena Therapeutics, we are driven by a shared mission: to restore and preserve vision for those affected by #InheritedRetinalDiseases. Our journey is fueled by passion, innovation and a deep commitment to making a difference in patients' lives.   In this video, you'll get an inside look at the heart of Atsena—the leaders and founders (Shannon Boye, Sanford Boye, Patrick Ritschel, Kenji Fujita) who have dedicated their careers to pioneering #GeneTherapy treatments that address unmet medical needs.    We’re excited to share our story with you and invite you to learn more about the people who are shaping the future of vision restoration.   Visual description: In this image, a woman wearing a white lab coat is speaking with a man in a medical research facility. The woman is smiling at the camera while pointing to a computer screen that is displaying a scientific image.